SCHEMBL3595771

SCHEMBL3595771

[CH2]CCCCCCCCCCCCCCCCCCCCCCCCO

nearest known ligand 0.44

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.44
ALDH1A1 P00352 2/20 0.44
TSHR P16473 2/20 0.44
HSD17B10 Q99714 1/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.39
GPR84 Q9NQS5 1/20 0.38
FFAR1 O14842 1/20 0.38
FFAR4 Q5NUL3 1/20 0.38
MIF P14174 1/20 0.33
CA12 O43570 1/20 0.31
CA1 P00915 1/20 0.31
CA2 P00918 1/20 0.31
CA9 Q16790 1/20 0.31
KDM4E B2RXH2 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4755734 1.00 LMNA (0.44) LMNAALDH1A1TSHRHSD17B10MEN1
SCHEMBL1272496 1.00 LMNA (0.44) LMNAALDH1A1TSHRHSD17B10MEN1
SCHEMBL4756817 1.00 LMNA (0.44) LMNAALDH1A1TSHRHSD17B10MEN1
SCHEMBL50290 1.00
SCHEMBL231055 1.00 LMNA (0.44) LMNAALDH1A1TSHRHSD17B10MEN1
SCHEMBL1881247 1.00 LMNA (0.44) LMNAALDH1A1TSHRHSD17B10MEN1
SCHEMBL337457 1.00 LMNA (0.44) LMNAALDH1A1TSHRHSD17B10MEN1
SCHEMBL50313 1.00
SCHEMBL1435928 1.00 LMNA (0.44) LMNAALDH1A1TSHRHSD17B10MEN1
SCHEMBL1875895 1.00 LMNA (0.44) LMNAALDH1A1TSHRHSD17B10MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4329730-A2 A SPECIFIC COMBINATION OF LIPIDS AND METHODS AND USES RELATED THERETO Helsingin Yliopisto (FI) 2024-03-06 EP disclosed
US-7741242-B2 Prepared by crosslinking a homogenized an addition polymer containing units from an unsaturated aryl-containing glycidyl ether or ester and an unsaturated alcohol or carboxylic acid and a zero-valent Pd compound to physically deposit the Pd compound on the polymer; oxidizing alcohols to aldehydes WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 2010-06-22 US disclosed
EP-1537913-B1 PALLADIUM CATALYST COMPOSITION WAKO PURE CHEMICAL INDUSTIES L (JP) 2009-07-01 EP disclosed
WO-2008110612-A2 NOVEL COMPOUNDS AND LUBRICATING COMPOSITIONS COMPRISING THE SAME SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V. (NL) 2008-09-18 WO disclosed
US-20060019822-A1 Palladium catalyst composition JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2006-01-26 US disclosed
EP-1537913-A1 PALLADIUM CATALYST COMPOSITION Wako Pure Chemical Industies, Ltd. (JP) 2005-06-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060019822-A1 Palladium catalyst composition ODC1, NUDC, ADH1C LMNA 3521/4885ALDH1A1 244/4885TSHR 4750/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.